U.S. Pharmaceutical Sterility Testing Market Size, Share & Trends Analysis Report By Type (In-house, Outsourcing), By Test Type, By End-use, By Sample (Sterile Drugs, Biologics & Therapeutics), And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
U.S. Pharmaceutical Sterility Testing Market Growth & Trends
The U.S. pharmaceutical sterility testing market size is anticipated to reach USD 1.18 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.9% from 2022 to 2030. Supportive government investment in the healthcare industry, increasing R&D activities, and growing demand for new therapeutics in the country are the key factors driving the growth. The majority of clinical trials worldwide are performed in the U.S. alone.
According to ClinicalTrials.gov, as of October 2022, over 31% of global clinical trials were registered in the U.S. alone. This is due to the significant number of initiatives taken by public organizations in the country to support R&D activities. The presence of technologically advanced infrastructure and an increase in R&D investment by pharmaceutical companies are also supporting clinical trials in the country. This is expected to improve the number of new medications and medical devices in the coming years in the U.S. and support the market in the post-pandemic period.
The government is keen on bringing down healthcare costs, which is anticipated to encourage the U.S. Food and Drug Administration (FDA) to promote the fast approval of generic pharmaceuticals. Faster approvals drive the need for newer sterility testing methods. This is anticipated to encourage market participants to spend more on sterility solutions and, in turn, expand the market. With an increasing demand for drugs, companies are launching new drugs with different routes of administration, dosage, and indication. These launches require thorough sterility testing and, thus, are anticipated to drive the industry’s growth.
The majority of pharmaceutical companies, biopharmaceutical companies, CROs, and CMOs are headquartered in the U.S. Companies such as Catalent, Inc., Pfizer Inc., AbbVie, Merck; Co. Johnson & Johnson, and Abbott are located in the U.S. The high number of pharmaceutical companies, biopharmaceutical companies, CMOs, and CROs located in the U.S. contributes to the high demand for sterility testing of pharmaceuticals, thus supporting the market growth.
The country suffers from a high burden of cancer. Due to this, government-based research institutes in the U.S. are constantly trying to improve cancer research funding in the country. For instance, in May 2022, the American Institute of Cancer Research stated that it had funded more than USD 110 million in cancer research in 2022, and it intends to fund more in the coming years to reduce the burden of cancer. Such initiatives are expected to increase the number of new medications for cancer in the coming years, thus increasing the demand for sterility testing of cancer drugs in the post-pandemic period.
U.S. Pharmaceutical Sterility Testing Market Report Highlights
U.S. Pharmaceutical Sterility Testing Market Growth & Trends
The U.S. pharmaceutical sterility testing market size is anticipated to reach USD 1.18 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.9% from 2022 to 2030. Supportive government investment in the healthcare industry, increasing R&D activities, and growing demand for new therapeutics in the country are the key factors driving the growth. The majority of clinical trials worldwide are performed in the U.S. alone.
According to ClinicalTrials.gov, as of October 2022, over 31% of global clinical trials were registered in the U.S. alone. This is due to the significant number of initiatives taken by public organizations in the country to support R&D activities. The presence of technologically advanced infrastructure and an increase in R&D investment by pharmaceutical companies are also supporting clinical trials in the country. This is expected to improve the number of new medications and medical devices in the coming years in the U.S. and support the market in the post-pandemic period.
The government is keen on bringing down healthcare costs, which is anticipated to encourage the U.S. Food and Drug Administration (FDA) to promote the fast approval of generic pharmaceuticals. Faster approvals drive the need for newer sterility testing methods. This is anticipated to encourage market participants to spend more on sterility solutions and, in turn, expand the market. With an increasing demand for drugs, companies are launching new drugs with different routes of administration, dosage, and indication. These launches require thorough sterility testing and, thus, are anticipated to drive the industry’s growth.
The majority of pharmaceutical companies, biopharmaceutical companies, CROs, and CMOs are headquartered in the U.S. Companies such as Catalent, Inc., Pfizer Inc., AbbVie, Merck; Co. Johnson & Johnson, and Abbott are located in the U.S. The high number of pharmaceutical companies, biopharmaceutical companies, CMOs, and CROs located in the U.S. contributes to the high demand for sterility testing of pharmaceuticals, thus supporting the market growth.
The country suffers from a high burden of cancer. Due to this, government-based research institutes in the U.S. are constantly trying to improve cancer research funding in the country. For instance, in May 2022, the American Institute of Cancer Research stated that it had funded more than USD 110 million in cancer research in 2022, and it intends to fund more in the coming years to reduce the burden of cancer. Such initiatives are expected to increase the number of new medications for cancer in the coming years, thus increasing the demand for sterility testing of cancer drugs in the post-pandemic period.
U.S. Pharmaceutical Sterility Testing Market Report Highlights
- Outsourcing emerged as the largest segment in 2021 with a share of 45.2%, as pharmaceutical and biopharmaceutical companies are trying to reduce expenses and hence outsourcing non-core functions such as sterility testing
- The sterility testing segment, by test type is expected to witness the fastest CAGR of 11.3% across the forecast as these tests are recommended by regulatory authorities such as the USFDA
- Based on product type, the kits and reagents segment held the largest share of 59.7% in 2021, due to the high consumption of these products in sterility testing
- The biopharmaceuticals segment by the sample is expected to grow at the fastest rate of 11.2% CAGR across the forecast owing to the growing demand for biologics such as vaccines, and monoclonal antibodies in the country for treating chronic and infectious diseases
- Based on end-use, the pharmaceutical companies accounted for the largest share of 42.9% in 2021, owing to the growing number of drug recalls due to lack of sterility, thus supporting segment growth
CHAPTER 1 METHODOLOGY AND SCOPE
1.1.Market Segmentation & Scope
1.1.1.Type
1.1.2.Product Type
1.1.3.Test Type
1.1.4.Sample
1.1.5.End-Use
1.1.6.Regional Scope
1.1.7.Estimates And Forecast Timeline
1.2.Research Methodology
1.3.Information Procurement
1.3.1.Purchased Database
1.3.2.GVR’s Internal Database
1.3.3.Secondary Sources
1.3.4.Primary Research
1.3.5.Details Of Primary Research
1.4.Information Or Data Analysis
1.4.1.Data Analysis Models
1.5.Market Formulation & Validation
1.6.Model Details
1.6.1.Commodity Flow Analysis (Model 1)
1.6.1.1.Approach 1: Commodity Flow Approach
1.6.2.Volume Price Analysis (Model 2)
1.6.2.1.Approach 2: Volume Price Analysis
1.7.List Of Secondary Sources
1.8.List Of Primary Sources
1.9.Objectives
1.9.1.Objective
1.9.2.Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1.Market Outlook
CHAPTER 3 U.S. PHARMACEUTICAL STERILITY TESTING MARKET VARIABLES, TRENDS & SCOPE
3.1.Market Lineage Outlook
3.1.1.Parent Market Outlook
3.1.2.Related/Ancillary Market Outlook
3.2.Penetration & Growth Prospect Mapping
3.3.Market Dynamics
3.3.1.Market Driver Analysis
3.3.1.1.Supportive Government Investment In The Healthcare Industry
3.3.1.2.Increasing R&D Activities
3.3.1.3.Increasing Number Of Drug Launches
3.3.1.4.Increasing Focus On Quality And Sterility
3.3.2.Market Restraint Analysis
3.3.2.1.Third-Party Performance
3.4.U.S. Pharmaceutical Sterility Testing Market Analysis Tools
3.4.1.Porter’s Five Forces Analysis
3.4.2.PESTLE Analysis
3.4.3.Major Deals & Strategic Alliances Analysis
3.4.3.1.Mergers And Acquisition
3.4.3.2.Expansions
3.4.3.3.Agreements And Collaborations
3.4.3.4.Product And Service Launches
3.5.Covid-19 Impact And Reformation Strategy
CHAPTER 4 U.S. PHARMACEUTICAL STERILITY TESTING MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1.Definitions And Scope
4.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
4.2.1.In-House Pharmaceutical Sterility Testing
4.2.1.1.In-House Pharmaceutical Sterility Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
4.2.2.Outsourcing Pharmaceutical Sterility Testing
4.2.2.1.Outsourcing Pharmaceutical Sterility Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 5 U.S. PHARMACEUTICAL STERILITY TESTING MARKET: PRODUCT TYPE ESTIMATES & TREND ANALYSIS
5.1.Definitions And Scope
5.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
5.2.1.Kits And Reagents
5.2.1.1.Kits And Reagents Market Estimates And Forecast 2018 - 2030 (USD Million)
5.2.2.Instruments
5.2.2.1.Instruments Market Estimates And Forecast 2018 - 2030 (USD Million)
5.2.3.Service
5.2.3.1.Service Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 6 U.S. PHARMACEUTICAL STERILITY TESTING MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS
6.1.Definitions And Scope
6.2. U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
6.2.1.Sterility Testing
6.2.1.1.Sterility Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
6.2.1.2.Membrane Filtration
6.2.1.2.1.Membrane Filtration Market Estimates And Forecast 2018 - 2030 (USD Million)
6.2.1.3.Direct Inoculation
6.2.1.3.1.Direct Inoculation Market Estimates And Forecast 2018 - 2030 (USD Million)
6.2.1.4.Product Flush
6.2.1.4.1.Product Flush Market Estimates And Forecast 2018 - 2030 (USD Million)
6.2.2.Bioburden Testing
6.2.2.1.Bioburden Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
6.2.3.Bacterial Endotoxin Testing
6.2.3.1.Bacterial Endotoxin Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 7 U.S. PHARMACEUTICAL STERILITY TESTING MARKET: SAMPLE ESTIMATES & TREND ANALYSIS
7.1.Definitions And Scope
7.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
7.2.1.Pharmaceuticals
7.2.1.1.Pharmaceuticals Market Estimates And Forecast 2018 - 2030 (USD Million)
7.2.2.Medical Devices
7.2.2.1.Medical Devices Market Estimates And Forecast 2018 - 2030 (USD Million)
7.2.3.Biopharmaceuticals
7.2.3.1.Biopharmaceuticals Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 8 U.S. PHARMACEUTICAL STERILITY TESTING MARKET: END-USE ESTIMATES & TREND ANALYSIS
8.1.Definitions And Scope
8.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
8.2.1.Compounding Pharmacies
8.2.1.1.Compounding Pharmacies Market Estimates And Forecast 2018 - 2030 (USD Million)
8.2.2.Medical Devices Companies
8.2.2.1.Medical Devices Companies Market Estimates And Forecast 2018 - 2030 (USD Million)
8.2.3.Pharmaceutical Companies
8.2.3.1.Pharmaceutical Companies Market Estimates And Forecast 2018 - 2030 (USD Million)
8.2.4.Others
8.2.4.1.Other Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 9 COMPETITIVE ANALYSIS
9.1.Recent Developments & Impact Analysis, By Key Market Participant
9.2.Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
9.3.Participant Categorization
9.3.1.Innovators
9.3.1.1.STERIS
9.3.1.2.Boston Analytical
9.3.1.3.Charles River Laboratories
9.3.1.4.SGS SA
9.4.Vendor Landscape
9.4.1.List Of Key Service Providers
9.4.2.Market Differentiators
9.4.3.U.S. Pharmaceutical Sterility Testing Market Share Analysis
CHAPTER 10 COMPETITIVE LANDSCAPE
10.1.Company Profiles
10.1.1.SGS SA
10.1.1.1.Company Overview
10.1.1.2.Service Benchmarking
10.1.1.3.Strategic Initiatives
10.1.2.Laboratory Corporation of America Holdings
10.1.2.1.Company Overview
10.1.2.2.Financial Performance
10.1.2.3.Service Benchmarking
10.1.2.4.Strategic Initiatives
10.1.3.Boston Analytical
10.1.3.1.Company Overview
10.1.3.2.Financial Performance
10.1.3.3.Service Benchmarking
10.1.3.4.Strategic Initiatives
10.1.4. Charles River Laboratories
10.1.4.1.Company Overview
10.1.4.2.Financial Performance
10.1.4.3.Service Benchmarking
10.1.4.4.Strategic Initiatives
10.1.5.Pacific Biolabs
10.1.5.1.Company Overview
10.1.5.2.Financial Performance
10.1.5.3.Service Benchmarking
10.1.5.4.Strategic Initiatives
10.1.6.STERIS
10.1.6.1.Company Overview
10.1.6.2.Financial Performance
10.1.6.3.Service Benchmarking
10.1.6.4.Strategic Initiatives
10.1.7. Pace Analytical
10.1.7.1.Company Overview
10.1.7.2.Financial Performance
10.1.7.3.Service Benchmarking
10.1.7.4.Strategic Initiatives
10.1.8.Nelson Laboratories, LLC
10.1.8.1.Company Overview
10.1.8.2.Financial Performance
10.1.8.3.Service Benchmarking
10.1.8.4.Strategic Initiatives
10.1.9.Infinity Laboratories
10.1.9.1.Company Overview
10.1.9.2.Financial Performance
10.1.9.3.Service Benchmarking
10.1.9.4.Strategic Initiatives
10.1.10.Thermo Fisher Scientific, Inc.
10.1.10.1.Company Overview
10.1.10.2.Financial Performance
10.1.10.3.Service Benchmarking
10.1.10.4.Strategic Initiatives
1.1.Market Segmentation & Scope
1.1.1.Type
1.1.2.Product Type
1.1.3.Test Type
1.1.4.Sample
1.1.5.End-Use
1.1.6.Regional Scope
1.1.7.Estimates And Forecast Timeline
1.2.Research Methodology
1.3.Information Procurement
1.3.1.Purchased Database
1.3.2.GVR’s Internal Database
1.3.3.Secondary Sources
1.3.4.Primary Research
1.3.5.Details Of Primary Research
1.4.Information Or Data Analysis
1.4.1.Data Analysis Models
1.5.Market Formulation & Validation
1.6.Model Details
1.6.1.Commodity Flow Analysis (Model 1)
1.6.1.1.Approach 1: Commodity Flow Approach
1.6.2.Volume Price Analysis (Model 2)
1.6.2.1.Approach 2: Volume Price Analysis
1.7.List Of Secondary Sources
1.8.List Of Primary Sources
1.9.Objectives
1.9.1.Objective
1.9.2.Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1.Market Outlook
CHAPTER 3 U.S. PHARMACEUTICAL STERILITY TESTING MARKET VARIABLES, TRENDS & SCOPE
3.1.Market Lineage Outlook
3.1.1.Parent Market Outlook
3.1.2.Related/Ancillary Market Outlook
3.2.Penetration & Growth Prospect Mapping
3.3.Market Dynamics
3.3.1.Market Driver Analysis
3.3.1.1.Supportive Government Investment In The Healthcare Industry
3.3.1.2.Increasing R&D Activities
3.3.1.3.Increasing Number Of Drug Launches
3.3.1.4.Increasing Focus On Quality And Sterility
3.3.2.Market Restraint Analysis
3.3.2.1.Third-Party Performance
3.4.U.S. Pharmaceutical Sterility Testing Market Analysis Tools
3.4.1.Porter’s Five Forces Analysis
3.4.2.PESTLE Analysis
3.4.3.Major Deals & Strategic Alliances Analysis
3.4.3.1.Mergers And Acquisition
3.4.3.2.Expansions
3.4.3.3.Agreements And Collaborations
3.4.3.4.Product And Service Launches
3.5.Covid-19 Impact And Reformation Strategy
CHAPTER 4 U.S. PHARMACEUTICAL STERILITY TESTING MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1.Definitions And Scope
4.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
4.2.1.In-House Pharmaceutical Sterility Testing
4.2.1.1.In-House Pharmaceutical Sterility Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
4.2.2.Outsourcing Pharmaceutical Sterility Testing
4.2.2.1.Outsourcing Pharmaceutical Sterility Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 5 U.S. PHARMACEUTICAL STERILITY TESTING MARKET: PRODUCT TYPE ESTIMATES & TREND ANALYSIS
5.1.Definitions And Scope
5.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
5.2.1.Kits And Reagents
5.2.1.1.Kits And Reagents Market Estimates And Forecast 2018 - 2030 (USD Million)
5.2.2.Instruments
5.2.2.1.Instruments Market Estimates And Forecast 2018 - 2030 (USD Million)
5.2.3.Service
5.2.3.1.Service Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 6 U.S. PHARMACEUTICAL STERILITY TESTING MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS
6.1.Definitions And Scope
6.2. U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
6.2.1.Sterility Testing
6.2.1.1.Sterility Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
6.2.1.2.Membrane Filtration
6.2.1.2.1.Membrane Filtration Market Estimates And Forecast 2018 - 2030 (USD Million)
6.2.1.3.Direct Inoculation
6.2.1.3.1.Direct Inoculation Market Estimates And Forecast 2018 - 2030 (USD Million)
6.2.1.4.Product Flush
6.2.1.4.1.Product Flush Market Estimates And Forecast 2018 - 2030 (USD Million)
6.2.2.Bioburden Testing
6.2.2.1.Bioburden Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
6.2.3.Bacterial Endotoxin Testing
6.2.3.1.Bacterial Endotoxin Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 7 U.S. PHARMACEUTICAL STERILITY TESTING MARKET: SAMPLE ESTIMATES & TREND ANALYSIS
7.1.Definitions And Scope
7.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
7.2.1.Pharmaceuticals
7.2.1.1.Pharmaceuticals Market Estimates And Forecast 2018 - 2030 (USD Million)
7.2.2.Medical Devices
7.2.2.1.Medical Devices Market Estimates And Forecast 2018 - 2030 (USD Million)
7.2.3.Biopharmaceuticals
7.2.3.1.Biopharmaceuticals Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 8 U.S. PHARMACEUTICAL STERILITY TESTING MARKET: END-USE ESTIMATES & TREND ANALYSIS
8.1.Definitions And Scope
8.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
8.2.1.Compounding Pharmacies
8.2.1.1.Compounding Pharmacies Market Estimates And Forecast 2018 - 2030 (USD Million)
8.2.2.Medical Devices Companies
8.2.2.1.Medical Devices Companies Market Estimates And Forecast 2018 - 2030 (USD Million)
8.2.3.Pharmaceutical Companies
8.2.3.1.Pharmaceutical Companies Market Estimates And Forecast 2018 - 2030 (USD Million)
8.2.4.Others
8.2.4.1.Other Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 9 COMPETITIVE ANALYSIS
9.1.Recent Developments & Impact Analysis, By Key Market Participant
9.2.Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
9.3.Participant Categorization
9.3.1.Innovators
9.3.1.1.STERIS
9.3.1.2.Boston Analytical
9.3.1.3.Charles River Laboratories
9.3.1.4.SGS SA
9.4.Vendor Landscape
9.4.1.List Of Key Service Providers
9.4.2.Market Differentiators
9.4.3.U.S. Pharmaceutical Sterility Testing Market Share Analysis
CHAPTER 10 COMPETITIVE LANDSCAPE
10.1.Company Profiles
10.1.1.SGS SA
10.1.1.1.Company Overview
10.1.1.2.Service Benchmarking
10.1.1.3.Strategic Initiatives
10.1.2.Laboratory Corporation of America Holdings
10.1.2.1.Company Overview
10.1.2.2.Financial Performance
10.1.2.3.Service Benchmarking
10.1.2.4.Strategic Initiatives
10.1.3.Boston Analytical
10.1.3.1.Company Overview
10.1.3.2.Financial Performance
10.1.3.3.Service Benchmarking
10.1.3.4.Strategic Initiatives
10.1.4. Charles River Laboratories
10.1.4.1.Company Overview
10.1.4.2.Financial Performance
10.1.4.3.Service Benchmarking
10.1.4.4.Strategic Initiatives
10.1.5.Pacific Biolabs
10.1.5.1.Company Overview
10.1.5.2.Financial Performance
10.1.5.3.Service Benchmarking
10.1.5.4.Strategic Initiatives
10.1.6.STERIS
10.1.6.1.Company Overview
10.1.6.2.Financial Performance
10.1.6.3.Service Benchmarking
10.1.6.4.Strategic Initiatives
10.1.7. Pace Analytical
10.1.7.1.Company Overview
10.1.7.2.Financial Performance
10.1.7.3.Service Benchmarking
10.1.7.4.Strategic Initiatives
10.1.8.Nelson Laboratories, LLC
10.1.8.1.Company Overview
10.1.8.2.Financial Performance
10.1.8.3.Service Benchmarking
10.1.8.4.Strategic Initiatives
10.1.9.Infinity Laboratories
10.1.9.1.Company Overview
10.1.9.2.Financial Performance
10.1.9.3.Service Benchmarking
10.1.9.4.Strategic Initiatives
10.1.10.Thermo Fisher Scientific, Inc.
10.1.10.1.Company Overview
10.1.10.2.Financial Performance
10.1.10.3.Service Benchmarking
10.1.10.4.Strategic Initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 1 List of secondary sources
Table 2 List of Abbreviations
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 U.S. pharmaceutical sterility testing market snapshot (2021)
Fig. 11 U.S. pharmaceutical sterility testing market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 U.S. pharmaceutical sterility testing market type outlook: Segment dashboard
Fig. 18 U.S. pharmaceutical sterility testing market: Type movement analysis
Fig. 19 In-house U.S. pharmaceutical sterility testing market 2018 - 2030 (USD Million)
Fig. 20 Outsourcing U.S. pharmaceutical sterility testing market 2018 - 2030 (USD Million)
Fig. 21 U.S. pharmaceutical sterility testing market product type outlook: Segment dashboard
Fig. 22 U.S. pharmaceutical sterility testing market: Product type movement analysis
Fig. 23 Kits and Reagents market 2018 - 2030 (USD Million)
Fig. 24 Instruments market 2018 - 2030 (USD Million)
Fig. 25 Service testing market 2018 - 2030 (USD Million)
Fig. 26 U.S. pharmaceutical sterility testing market test type outlook: Segment dashboard
Fig. 27 U.S. pharmaceutical sterility testing market: Test type movement analysis
Fig. 28 Sterility testing market 2018 - 2030 (USD Million)
Fig. 29 Membrane Filtration market 2018 - 2030 (USD Million)
Fig. 30 Direct Inoculation market 2018 - 2030 (USD Million)
Fig. 31 Bioburden testing market 2018 - 2030 (USD Million)
Fig. 32 Bacterial endotoxin testing market 2018 - 2030 (USD Million)
Fig. 33 Container closure integrity testing market 2018 - 2030 (USD Million)
Fig. 34 Rapid micro test market 2018 - 2030 (USD Million)
Fig. 35 ATP bioluminescence market 2018 - 2030 (USD Million)
Fig. 36 Fluorescent labeling market 2018 - 2030 (USD Million)
Fig. 37 Electrical resistance market 2018 - 2030 (USD Million)
Fig. 38 Others market 2018 - 2030 (USD Million)
Fig. 39 Antimicrobial effectiveness testing market 2018 - 2030 (USD Million)
Fig. 40 U.S. pharmaceutical sterility testing market sample outlook: Segment dashboard
Fig. 41 U.S. pharmaceutical sterility testing market: Sample movement analysis
Fig. 42 Pharmaceuticals market 2018 - 2030 (USD Million)
Fig. 43 Medical devices market 2018 - 2030 (USD Million)
Fig. 44 Biopharmaceuticals market 2018 - 2030 (USD Million)
Fig. 45 U.S. pharmaceutical sterility testing market: Sample movement analysis
Fig. 46 U.S. pharmaceutical sterility testing market end-use outlook: Segment dashboard
Fig. 47 U.S. pharmaceutical sterility testing market: End-use movement analysis
Fig. 48 Compounding Pharmacies market 2018 - 2030 (USD Million)
Fig. 49 Medical devices companies market 2018 - 2030 (USD Million)
Fig. 50 Pharmaceutical companies market 2018 - 2030 (USD Million)
Fig. 51 Others market 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 U.S. pharmaceutical sterility testing market snapshot (2021)
Fig. 11 U.S. pharmaceutical sterility testing market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 U.S. pharmaceutical sterility testing market type outlook: Segment dashboard
Fig. 18 U.S. pharmaceutical sterility testing market: Type movement analysis
Fig. 19 In-house U.S. pharmaceutical sterility testing market 2018 - 2030 (USD Million)
Fig. 20 Outsourcing U.S. pharmaceutical sterility testing market 2018 - 2030 (USD Million)
Fig. 21 U.S. pharmaceutical sterility testing market product type outlook: Segment dashboard
Fig. 22 U.S. pharmaceutical sterility testing market: Product type movement analysis
Fig. 23 Kits and Reagents market 2018 - 2030 (USD Million)
Fig. 24 Instruments market 2018 - 2030 (USD Million)
Fig. 25 Service testing market 2018 - 2030 (USD Million)
Fig. 26 U.S. pharmaceutical sterility testing market test type outlook: Segment dashboard
Fig. 27 U.S. pharmaceutical sterility testing market: Test type movement analysis
Fig. 28 Sterility testing market 2018 - 2030 (USD Million)
Fig. 29 Membrane Filtration market 2018 - 2030 (USD Million)
Fig. 30 Direct Inoculation market 2018 - 2030 (USD Million)
Fig. 31 Bioburden testing market 2018 - 2030 (USD Million)
Fig. 32 Bacterial endotoxin testing market 2018 - 2030 (USD Million)
Fig. 33 Container closure integrity testing market 2018 - 2030 (USD Million)
Fig. 34 Rapid micro test market 2018 - 2030 (USD Million)
Fig. 35 ATP bioluminescence market 2018 - 2030 (USD Million)
Fig. 36 Fluorescent labeling market 2018 - 2030 (USD Million)
Fig. 37 Electrical resistance market 2018 - 2030 (USD Million)
Fig. 38 Others market 2018 - 2030 (USD Million)
Fig. 39 Antimicrobial effectiveness testing market 2018 - 2030 (USD Million)
Fig. 40 U.S. pharmaceutical sterility testing market sample outlook: Segment dashboard
Fig. 41 U.S. pharmaceutical sterility testing market: Sample movement analysis
Fig. 42 Pharmaceuticals market 2018 - 2030 (USD Million)
Fig. 43 Medical devices market 2018 - 2030 (USD Million)
Fig. 44 Biopharmaceuticals market 2018 - 2030 (USD Million)
Fig. 45 U.S. pharmaceutical sterility testing market: Sample movement analysis
Fig. 46 U.S. pharmaceutical sterility testing market end-use outlook: Segment dashboard
Fig. 47 U.S. pharmaceutical sterility testing market: End-use movement analysis
Fig. 48 Compounding Pharmacies market 2018 - 2030 (USD Million)
Fig. 49 Medical devices companies market 2018 - 2030 (USD Million)
Fig. 50 Pharmaceutical companies market 2018 - 2030 (USD Million)
Fig. 51 Others market 2018 - 2030 (USD Million)
